[go: up one dir, main page]

MX391999B - Piridinas y su uso en el tratamiento del cáncer. - Google Patents

Piridinas y su uso en el tratamiento del cáncer.

Info

Publication number
MX391999B
MX391999B MX2018001576A MX2018001576A MX391999B MX 391999 B MX391999 B MX 391999B MX 2018001576 A MX2018001576 A MX 2018001576A MX 2018001576 A MX2018001576 A MX 2018001576A MX 391999 B MX391999 B MX 391999B
Authority
MX
Mexico
Prior art keywords
sup
pyridines
cancer treatment
compounds
treatment
Prior art date
Application number
MX2018001576A
Other languages
English (en)
Other versions
MX2018001576A (es
Inventor
Ajit Jadhav
Anton Simeonov
David Joseph Maloney
Diane Karen Luci
Nathan Patrick Coussens
Thomas S Dexheimer
William Chester Stafford
Original Assignee
Elias Set Jenoe Arner
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elias Set Jenoe Arner, Us Health filed Critical Elias Set Jenoe Arner
Publication of MX2018001576A publication Critical patent/MX2018001576A/es
Publication of MX391999B publication Critical patent/MX391999B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan compuestos de la Fórmula (I)(ver formula) (I) o sales de aquellos aceptables desde el punto de vista farmacéutico, en donde L, R1, R2, R3, R4 y n tienen significados proporcionados en la descripción, en donde los compuestos son útiles en el tratamiento de tipos de cáncer.
MX2018001576A 2015-08-07 2016-08-05 Piridinas y su uso en el tratamiento del cáncer. MX391999B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1514021.3A GB201514021D0 (en) 2015-08-07 2015-08-07 Novel Pyridines and their use in the treatment of cancer
PCT/US2016/045731 WO2017027359A1 (en) 2015-08-07 2016-08-05 Pyridines and their use in the treatment of cancer

Publications (2)

Publication Number Publication Date
MX2018001576A MX2018001576A (es) 2018-11-09
MX391999B true MX391999B (es) 2025-03-21

Family

ID=54200423

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001576A MX391999B (es) 2015-08-07 2016-08-05 Piridinas y su uso en el tratamiento del cáncer.

Country Status (12)

Country Link
US (1) US10899710B2 (es)
EP (1) EP3331858A1 (es)
JP (1) JP6636153B2 (es)
KR (1) KR102180934B1 (es)
CN (1) CN108026044A (es)
AU (1) AU2016306276B2 (es)
CA (1) CA2995077C (es)
GB (1) GB201514021D0 (es)
MA (1) MA42915A (es)
MX (1) MX391999B (es)
RU (1) RU2730505C2 (es)
WO (1) WO2017027359A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201514021D0 (en) 2015-08-07 2015-09-23 Arner Elias Set Jeno Novel Pyridines and their use in the treatment of cancer
BR112018074118B1 (pt) * 2016-05-24 2023-03-14 Basf Se Uracilpiridinas, haletos ácidos, intermediários, composição herbicida, processo de preparação de composições ativas como herbicidas, método de controle de vegetação indesejada e uso da uracilpiridina
JP2020507625A (ja) 2017-02-07 2020-03-12 オブリーク セラピューティクス アーベー ヘテロアリールスルホニル置換ピリジンおよび癌の治療におけるそれらの使用
KR20190115011A (ko) 2017-02-07 2019-10-10 오블리크 세러퓨틱스 에이비 설피닐피리딘 및 암의 치료에서 이의 용도
CA3051538A1 (en) 2017-02-07 2018-08-16 Oblique Therapeutics Ab Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer
MA47458A (fr) * 2017-02-07 2019-12-18 Oblique Therapeutics Ab Pyridines à substitution hydrocarbylsulfonyle et leur utilisation dans le traitement du cancer
CN111867587A (zh) * 2018-02-12 2020-10-30 信达制药公司 用于治疗癌症的硫氧还蛋白还原酶抑制剂
EP3959199A4 (en) * 2019-04-24 2023-06-28 Memorial Sloan Kettering Cancer Center Compositions and methods for treating ras-mutant cancers

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE4643T1 (de) 1979-12-19 1983-09-15 Duphar International Research B.V Nitrothiophene, verfahren zur herstellung der verbindungen sowie fungizide und/oder bakterizide zusammensetzungen auf der basis dieser verbindungen.
US4456469A (en) 1980-03-07 1984-06-26 E. I. Du Pont De Nemours And Company Pyridyl sulfone herbicides
AU543161B2 (en) 1980-03-07 1985-04-04 E.I. Du Pont De Nemours And Company Pyrimidine or s.triazine derivatives
US4791127A (en) 1985-10-07 1988-12-13 Nippon Kayaku Kabushiki Kaisha Alkanesulfonate derivatives and their use as insecticides, acaricides or nematicides
DE3812177A1 (de) 1988-04-13 1989-10-26 Bayer Ag 2-phenylsulfinyl-nitro-pyridine, verfahren zu ihrer herstellung und ihre verwendung
AU2395095A (en) 1994-04-29 1995-11-29 G.D. Searle & Co. Method of using (h+/k+) atpase inhibitors as antiviral agents
DE19531148A1 (de) 1995-08-24 1997-02-27 Basf Ag Fungizide Pyridin-2-yl-Derivate
AU6926596A (en) 1995-08-24 1997-03-19 Basf Aktiengesellschaft N-heterocyclic compounds, intermediate products used to prepare them, agents containing them and their use in antifungal applications
JP2002507197A (ja) 1997-05-30 2002-03-05 ビーエーエスエフ アクチェンゲゼルシャフト 置換チオピリジン
US6284923B1 (en) 1997-08-22 2001-09-04 Tularik Inc Substituted benzene compounds as antiproliferative and cholesterol lowering action
WO1999018096A1 (en) 1997-10-02 1999-04-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6191170B1 (en) * 1998-01-13 2001-02-20 Tularik Inc. Benzenesulfonamides and benzamides as therapeutic agents
DE69906397T2 (de) 1998-01-16 2004-02-19 F. Hoffmann-La Roche Ag Benzosulfonderivate
DK1259485T3 (da) 2000-02-29 2006-04-10 Millennium Pharm Inc Benzamider og beslægtede inhibitorer for faktor Xa
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
WO2003068744A1 (en) 2002-02-18 2003-08-21 Ishihara Sangyo Kaisha, Ltd. Pyridine derivatives or salts thereof and cytokine production inhibitors containing the same
US20030236287A1 (en) 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
US7037902B2 (en) 2002-07-03 2006-05-02 Receptron, Inc. Affinity small molecules for the EPO receptor
WO2005007621A2 (en) 2003-05-30 2005-01-27 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
ATE415397T1 (de) 2004-06-04 2008-12-15 Arena Pharm Inc Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen
US20060019967A1 (en) * 2004-07-21 2006-01-26 Su-Ying Wu SARS CoV main protease inhibitors
GB0426313D0 (en) 2004-12-01 2005-01-05 Merck Sharp & Dohme Therapeutic agents
WO2006083692A2 (en) 2005-01-28 2006-08-10 Mount Sinai Schoool Of Medicine Methods of identifying modulators of bromodomains
GB0504828D0 (en) 2005-03-09 2005-04-13 Merck Sharp & Dohme Therapeutic agents
EP1976495A2 (en) 2006-01-06 2008-10-08 Aarhus Universitet Compounds acting on the serotonin transporter
JP2009535307A (ja) 2006-04-28 2009-10-01 アベキサ・リミテッド インテグラーゼ阻害剤３
SG183036A1 (en) 2007-07-17 2012-08-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
CN101723932B (zh) 2008-10-31 2013-11-20 北京以岭生物工程技术有限公司 硝基吡啶乙烯亚胺化合物、其药物组合物及其制备方法和用途
WO2010138820A2 (en) 2009-05-28 2010-12-02 President And Fellows Of Harvard College N,n-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation
CA2771190C (en) 2009-08-17 2020-01-21 Memorial Sloan-Kettering Cancer Center Heat shock protein binding compounds, compositions, and methods for making and using same
US9206125B2 (en) 2010-02-10 2015-12-08 Public University Corporation Yokohama City University Use of compound binding to mSin3B that specifically binds to neuron restrictive silencer factor (NRSF)
CN102206172B (zh) 2010-03-30 2015-02-25 中国医学科学院医药生物技术研究所 一组取代双芳基化合物及其制备方法和抗病毒应用
EP2609089A1 (en) 2010-08-27 2013-07-03 Universität des Saarlandes Selective 17beta-hydroxysteroid dehydrogenase type 1 inhibitors
US9539256B2 (en) 2012-02-10 2017-01-10 The Board Of Regents Of The University Of Texas System Modulators of exchange proteins directly activated by cAMP (EPACS)
JP6393322B2 (ja) * 2013-07-10 2018-09-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規なキラル窒素−リン配位子及びアルケン類の不斉水素化のためのその使用
CN104672214B (zh) 2013-12-03 2019-04-12 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
CN105503827B (zh) 2014-10-11 2019-09-24 上海翰森生物医药科技有限公司 Egfr抑制剂及其制备方法和用途
CN105085483B (zh) 2015-06-04 2019-01-01 湖北生物医药产业技术研究院有限公司 激酶抑制剂及其应用
CN104987324B (zh) 2015-06-04 2018-05-04 湖北生物医药产业技术研究院有限公司 作为alk抑制剂的嘧啶衍生物
GB201514021D0 (en) 2015-08-07 2015-09-23 Arner Elias Set Jeno Novel Pyridines and their use in the treatment of cancer
MA47458A (fr) 2017-02-07 2019-12-18 Oblique Therapeutics Ab Pyridines à substitution hydrocarbylsulfonyle et leur utilisation dans le traitement du cancer
CA3051538A1 (en) 2017-02-07 2018-08-16 Oblique Therapeutics Ab Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer
KR20190115011A (ko) 2017-02-07 2019-10-10 오블리크 세러퓨틱스 에이비 설피닐피리딘 및 암의 치료에서 이의 용도
JP2020507625A (ja) 2017-02-07 2020-03-12 オブリーク セラピューティクス アーベー ヘテロアリールスルホニル置換ピリジンおよび癌の治療におけるそれらの使用

Also Published As

Publication number Publication date
KR20180035904A (ko) 2018-04-06
JP2018525443A (ja) 2018-09-06
RU2018107879A (ru) 2019-09-09
JP6636153B2 (ja) 2020-01-29
WO2017027359A1 (en) 2017-02-16
RU2018107879A3 (es) 2019-09-09
US20200087260A1 (en) 2020-03-19
CN108026044A (zh) 2018-05-11
MX2018001576A (es) 2018-11-09
CA2995077C (en) 2020-04-21
CA2995077A1 (en) 2017-02-16
GB201514021D0 (en) 2015-09-23
EP3331858A1 (en) 2018-06-13
AU2016306276B2 (en) 2019-08-01
AU2016306276A1 (en) 2018-02-22
WO2017027359A8 (en) 2017-04-20
US10899710B2 (en) 2021-01-26
MA42915A (fr) 2018-08-01
KR102180934B1 (ko) 2020-11-20
RU2730505C2 (ru) 2020-08-24

Similar Documents

Publication Publication Date Title
MX391999B (es) Piridinas y su uso en el tratamiento del cáncer.
CY1124798T1 (el) Υποκατεστημενα παραγωγα καρβονουκλεοζιδιων χρησιμα ως παραγοντες κατα των καρκινων
CY1124055T1 (el) Ετεροκυκλικες ενωσεις ως ανοσοδιαμορφωτες
MX2020011558A (es) Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm.
ECSP19003773A (es) Compuestos heterocíclicos como inmunomoduladores
CL2019002304A1 (es) Compuestos para el tratamiento del cáncer.
MX391981B (es) Derivados de benzooxazol como inmunomoduladores.
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
MX392000B (es) Piridinas sustituidas con heteroarilsulfonilo y su uso en el tratamiento del cáncer.
PH12018500987A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
MX389800B (es) Piridinas sustituidas con heterociclilsulfonilo y su uso en el tratamiento del cancer
MX2018008362A (es) Derivados de quinolin-2-ona.
JOP20190254A1 (ar) مركبات مضادة للأورام
PH12018502497A1 (en) Adenosine derivatives for use in the treatment of cancer
MX388321B (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
MX392900B (es) Piridinas sustituidas con hidrocarbilsulfonilo y su uso en el tratamiento del cancer
MX2019009356A (es) Sulfinilpiridinas y su uso en el tratamiento del cancer.
EA201692358A1 (ru) Производные изоиндолина для применения в лечении вирусной инфекции
CL2015002897A1 (es) Inhibidores de bace1
CL2016001937A1 (es) Compuestos de benzopirano funcionalizados y uso de los mismos
TW201612253A (en) High wet fast disperse dyes and mixtures thereof
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
EA201791099A1 (ru) Хинолин карбоксамиды для применения в лечении лейкоза
WO2017027357A8 (en) Pyridazinones and their use in the treatment of cancer
MX395659B (es) Compuestos triciclicos y su uso en el tratamiento del cancer